Anavex Life Sciences saw the highest growth of 2.99% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Anavex Life Sciences‘s patent filings and grants. Buy the databook here.
Anavex Life Sciences has been focused on protecting inventions in Australia(AU) with four publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 75% filings and 50% grants. The Australia(AU), United States(US), and Canada(CA) patent Office are among the top ten patent offices where Anavex Life Sciences is filings its patents. Among the top granted patent authorities, Anavex Life Sciences has 50% of its grants in Australia(AU) and 50% in Canada(CA).
AbbVie could be the strongest competitor for Anavex Life Sciences
Anavex Life Sciences stands in second position with respect to its patent publications among its competitors.
Patents related to genomics and nanomedicine lead Anavex Life Sciences's portfolio
Anavex Life Sciences has the highest number of patents in genomics followed by, nanomedicine and rare diseases. For genomics, nearly 33% of patents were filed and no patents were granted in Q2 2024.
Cerebral palsy related patents lead Anavex Life Sciences portfolio followed by multiple sclerosis, and alzheimer's disease
Anavex Life Sciences has highest number of patents in cerebral palsy followed by multiple sclerosis, alzheimer's disease, pain, and neuropathic pain (neuralgia).
For comprehensive analysis of Anavex Life Sciences's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.